# SEMA7A Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- SEMA7A is a unique GPI-anchored semaphorin that signals through two distinct receptor systems: PLXNC1, mediating repulsive/inhibitory effects, and integrins (αvβ1, α5β1, α9β1), mediating adhesive/migratory signals, leading to context-dependent cellular responses.
- Pathogenic variants in SEMA7A are implicated in Kallmann syndrome, causing hypogonadotropic hypogonadism and anosmia due to disrupted GnRH neuron migration, and are also associated with the JMH blood group antigen system.
- Aberrant SEMA7A overexpression in numerous solid tumors drives invasion, metastasis, and immunosuppression, making it a prognostic biomarker and therapeutic target, with strategies including monoclonal antibodies and small-molecule inhibitors under development.
- SEMA7A plays pleiotropic roles in immune regulation, promoting M1 macrophage polarization and T cell costimulation, and is involved in cardiovascular pathologies like atherosclerosis and abdominal aortic aneurysm through its effects on endothelial and smooth muscle cells.
- The gene's regulatory landscape includes a large first intron with regulatory elements, a 3' UTR with microRNA binding sites, and alternative splicing events, all contributing to tight post-transcriptional control of SEMA7A expression.
- SEMA7A's structural features include a conserved SEMA domain forming a β-propeller fold, a PSI domain, and a C-terminal GPI-anchoring signal, with dimerization being crucial for its cell surface function and potential heterodimerization with SEMA4D impacting neural development.

---

## Executive Summary & Key Metadata

SEMA7A (Semaphorin 7A), also known as CD108, JMH blood group antigen, or GPI-Sema, is a glycosylphosphatidylinositol (GPI)-anchored membrane-associated semaphorin that functions as a bifunctional signaling molecule. It is unique among the eight subclasses of semaphorins (classes 1–7 and V) because it is the only GPI-linked member in vertebrates, lacking a conventional transmembrane domain. SEMA7A was initially characterized as a potent axon guidance molecule promoting axonal outgrowth in the olfactory bulb and central nervous system, but subsequent research has established its pleiotropic roles in immune regulation, bone homeostasis, angiogenesis, cancer progression, and metabolic control.

The gene product is a heavily glycosylated protein of approximately 75–80 kDa (reduced) that exists as a disulfide-linked dimer on the cell surface. It signals through two principal receptor systems: the plexin C1 (PLXNC1) receptor, which mediates repulsive or inhibitory signals in specific cellular contexts, and the integrin family (notably αvβ1, α5β1, and α9β1), which transduces adhesive and migratory signals. This dual-receptor utilization underpins the context-dependent functional dichotomy of SEMA7A—acting as either a promoter or inhibitor of cellular processes depending on the receptor repertoire expressed by the target cell.

The clinical relevance of SEMA7A spans multiple domains: it is a blood group antigen system (JMH) with implications in transfusion medicine; it harbors pathogenic variants causing Kallmann syndrome (hypogonadotropic hypogonadism with anosmia); it is aberrantly overexpressed in numerous solid tumors where it drives invasion, metastasis, and immunosuppression; and it contributes to cardiovascular pathologies including atherosclerosis and abdominal aortic aneurysm. This manual provides an exhaustive technical reference covering genomic architecture, structural biology, signaling mechanisms, pathogenic mutations, and therapeutic targeting of SEMA7A.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | SEMA7A |
| UniProt Accession | O75326 |
| Representative PDB ID | 3NVQ (SEMA domain), 4UX8 (SEMA7A/PLXNC1 complex) |
| Chromosomal Locus | 15q22.3–q23 (GRCh38: chr15:74,409,581–74,434,901) |
| Primary Molecular Function | GPI-anchored semaphorin; axon guidance; immune modulation; integrin/plexin signaling |
| Disease & Pathology Associations | Kallmann syndrome, JMH blood group antigens, multiple cancers, atherosclerosis, abdominal aortic aneurysm, atopic dermatitis, obesity, osteoporosis |
| Expression Pattern | Broad; highest in placenta, skeletal muscle, heart, kidney, and activated immune cells |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The SEMA7A gene is located on the long arm of chromosome 15 at cytogenetic band 15q22.3–q23. The reference genome assembly (GRCh38/hg38) places the gene between coordinates 74,409,581 and 74,434,901 on the plus strand. The gene spans approximately 25.3 kilobases (kb) of genomic DNA and comprises 15 exons and 14 introns. The coding sequence (CDS) is 2,094 nucleotides in length, encoding a precursor protein of 666 amino acids that undergoes proteolytic cleavage of a 45-amino-acid N-terminal signal peptide to yield the mature 621-amino-acid protein.

The genomic organization is notable for a large first intron (~8.5 kb) that contains multiple regulatory elements, including a CpG island spanning the promoter region and exon 1. This CpG island is subject to differential methylation in cancer, with hypermethylation associated with transcriptional silencing in some tumor types and hypomethylation correlating with overexpression in others. The promoter region lacks a canonical TATA box but contains multiple GC-boxes that serve as binding sites for the transcription factor SP1 (Specificity Protein 1). Additional transcription factor binding sites identified through ChIP-seq and promoter reporter assays include those for EGR2 (Early Growth Response 2), which has been shown to regulate SEMA7A expression in T cell anergy models, and SOX9, which drives SEMA7A expression in the postpartum mammary gland.

### 1.2 Regulatory Architecture and Enhancer Elements

The regulatory landscape of SEMA7A extends beyond the proximal promoter. Chromatin conformation capture studies (Hi-C) have identified several putative enhancer elements located in intron 1 and in the intergenic region approximately 15 kb upstream of the transcription start site (TSS). These enhancers are marked by H3K27ac and H3K4me1 histone modifications in tissues where SEMA7A is highly expressed, including placenta and activated macrophages. The intronic enhancer within intron 1 contains binding sites for the transcription factor CEBPB (CCAAT/Enhancer Binding Protein Beta), which is consistent with the strong upregulation of SEMA7A during monocyte-to-macrophage differentiation.

The 3' untranslated region (UTR) of SEMA7A is 1,847 nucleotides in length and contains multiple AU-rich elements (AREs) that confer mRNA instability. The RNA-binding protein Quaking (QKI) binds to these AREs and stabilizes the transcript, providing a post-transcriptional regulatory layer that controls SEMA7A protein abundance during macrophage differentiation. Additionally, the 3' UTR harbors binding sites for several microRNAs, including miR-28-5p, which negatively regulates SEMA7A expression in pancreatic cancer cells. The lncRNA LOXL1-AS1 functions as a competing endogenous RNA (ceRNA) that sponges miR-28-5p, thereby derepressing SEMA7A translation and promoting pancreatic cancer progression.

### 1.3 Alternative Splicing and Isoforms

The SEMA7A gene undergoes alternative splicing that generates multiple transcript variants. The canonical transcript (ENST00000298332.9) encodes the full-length GPI-anchored protein. A second transcript variant (ENST00000441276.5) results from alternative splicing of exon 10, which introduces a premature stop codon and produces a truncated protein lacking the C-terminal GPI-anchoring signal sequence. This variant, if translated, would produce a secreted form of SEMA7A; however, it is likely subject to nonsense-mediated mRNA decay (NMD) under physiological conditions.

A third transcript variant (ENST00000465483.1) retains intron 4, which introduces a frameshift and early termination. This variant is expressed at low levels in testis and brain and may encode a non-functional protein. The functional significance of these minor splice variants remains incompletely characterized, but their existence suggests that the cell exerts tight regulatory control over SEMA7A expression through multiple post-transcriptional mechanisms.

### 1.4 Phylogenetic Conservation

SEMA7A is highly conserved across vertebrates. The mouse ortholog (Sema7a) shares 92% amino acid identity with the human protein. The chick ortholog shows distinct expression patterns during embryonic development, particularly in the developing nervous system and somites. The high degree of conservation underscores the fundamental importance of SEMA7A in developmental processes, particularly in neural circuit formation and immune system development.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The SEMA7A precursor protein of 666 amino acids is organized into distinct functional domains from the N-terminus to the C-terminus:

1. **Signal peptide (residues 1–45):** Directs the nascent polypeptide to the endoplasmic reticulum (ER) for co-translational translocation into the secretory pathway. This sequence is cleaved by signal peptidase in the ER lumen.

2. **SEMA domain (residues 46–489):** The defining structural module of all semaphorins. This ~440-amino-acid domain adopts a conserved seven-bladed β-propeller fold. Each blade consists of four antiparallel β-strands arranged in a toroidal structure. The SEMA domain is responsible for receptor binding and contains the conserved semaphorin signature sequence. In SEMA7A, the SEMA domain mediates binding to both PLXNC1 and integrin receptors. The domain also contains a calcium-binding site that is essential for structural stability.

3. **PSI domain (residues 490–560):** Named after its presence in Plexins, Semaphorins, and Integrins. This domain contains a single disulfide bond and adopts a compact fold that stabilizes the junction between the SEMA domain and the C-terminal region. The PSI domain contributes to the overall rigidity of the extracellular portion of the protein.

4. **Ig-like domain (residues 561–620):** An immunoglobulin-like domain that is present in some semaphorins but absent in others. In SEMA7A, this domain is truncated and may contribute to protein-protein interactions or dimerization interfaces.

5. **GPI-anchoring signal (residues 621–666):** The C-terminal 45 amino acids contain a hydrophobic stretch that serves as a signal for GPI anchor addition. This sequence is cleaved in the ER and replaced by a pre-assembled GPI moiety that tethers the mature protein to the outer leaflet of the plasma membrane. The GPI anchor confers lateral mobility within the membrane and allows SEMA7A to partition into lipid rafts, which is critical for its signaling function.

### 2.2 Quaternary Structure and Dimerization

SEMA7A exists as a homodimer on the cell surface. The dimerization interface is formed primarily by the SEMA domains of two monomers, which associate in a "head-to-head" orientation. The dimer interface buries approximately 2,500 Ų of solvent-accessible surface area per monomer. The dimerization is stabilized by both hydrophobic interactions and a conserved disulfide bond involving cysteine residues at positions 480 and 483 in the PSI domain region.

Recent structural and biochemical studies have revealed that SEMA7A can also form heterodimers with SEMA4D (CD100). This heterodimerization occurs in cis (on the same cell surface) and is essential for the correct membrane targeting of both proteins in neocortical neurons. The SEMA7A/SEMA4D heterodimer is required for proper neocortical wiring during development, and disruption of this interaction leads to axonal pathfinding defects. The heterodimerization interface overlaps with the homodimerization interface, suggesting that the two processes are mutually exclusive and that the cell can regulate the balance between homo- and heterodimer formation.

### 2.3 Post-Translational Modifications

SEMA7A is heavily glycosylated, with five predicted N-linked glycosylation sites (Asn-X-Ser/Thr motifs) at positions 61, 115, 205, 346, and 407 within the SEMA domain. Mass spectrometry analysis has confirmed occupancy at all five sites with complex-type glycans. The glycosylation is essential for proper protein folding and trafficking through the secretory pathway; inhibition of N-glycosylation with tunicamycin results in ER retention and degradation of the protein. The glycans also contribute to the stability of the SEMA domain and may modulate receptor binding affinity.

The GPI anchor is a complex glycolipid structure containing phosphatidylinositol, glucosamine, three mannose residues, and a phosphoethanolamine linker. The lipid moiety is typically palmitoylated or stearoylated, which influences membrane microdomain partitioning. The GPI anchor can be cleaved by phospholipases, including GPI-phospholipase D (GPI-PLD), which releases soluble SEMA7A from the cell surface. This soluble form retains biological activity and can act at a distance from the producing cell, functioning as a diffusible cytokine-like molecule.

### 2.4 Structural Insights from Crystallography

The crystal structure of the SEMA7A SEMA domain has been determined at 2.8 Å resolution (PDB: 3NVQ). The structure confirms the seven-bladed β-propeller fold, with each blade composed of four antiparallel β-strands (A–D). The blades are arranged in a toroidal configuration with a central channel that is occupied by a calcium ion coordinated by conserved aspartate and asparagine residues. The top face of the propeller contains the receptor-binding surface, which includes a highly conserved arginine residue (Arg153) that is critical for PLXNC1 binding.

The co-crystal structure of SEMA7A with the PLXNC1 ectodomain (PDB: 4UX8) reveals that the SEMA domain of SEMA7A binds to the SEMA domain of PLXNC1 in a 1:1 stoichiometry. The binding interface is extensive, burying approximately 1,800 Ų of surface area, and involves residues from blades 2, 3, and 4 of the SEMA7A propeller. The interaction is dominated by electrostatic contacts, with a ring of basic residues on SEMA7A engaging acidic residues on PLXNC1. Mutational analysis has identified several critical contact residues, including Arg153, Asp155, and Glu157 on SEMA7A, which when mutated abolish PLXNC1 binding and downstream signaling.

### 2.5 Interactive 3D Visualization

For interactive exploration of the SEMA7A three-dimensional structure, including domain architecture, post-translational modifications, and receptor-binding interfaces, the following visualizer tool is recommended:

[Interactive 3D Protein Visualizer: Load SEMA7A (PDB: 3NVQ)](/tools/protein-structure-viewer?source=direct&pdbId=3NVQ)

This tool allows users to rotate the structure, color-code domains, display surface electrostatics, and highlight specific residues of interest, including known pathogenic mutation sites.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Receptor Systems and Signal Transduction

SEMA7A signals through two distinct receptor systems, each activating different downstream pathways:

#### 3.1.1 PLXNC1-Mediated Signaling

PLXNC1 (Plexin C1) is a single-pass transmembrane receptor that belongs to the plexin family. Unlike other plexins, PLXNC1 does not require neuropilin co-receptors for semaphorin binding. The binding of SEMA7A to PLXNC1 triggers a conformational change in the receptor that activates its intrinsic GTPase-activating protein (GAP) activity toward R-Ras and M-Ras. This GAP activity leads to the inactivation of R-Ras, which in turn inhibits integrin-mediated cell adhesion and promotes cytoskeletal collapse.

The PLXNC1 signaling cascade involves the following steps:

1. **SEMA7A binding** induces PLXNC1 dimerization and clustering in the plasma membrane.
2. **R-Ras GAP activation:** The cytoplasmic domain of PLXNC1 contains a GAP domain that hydrolyzes R-Ras-GTP to R-Ras-GDP, inactivating R-Ras.
3. **Integrin inactivation:** R-Ras-GTP is required for integrin activation and focal adhesion assembly. Its inactivation leads to reduced integrin affinity for extracellular matrix ligands, resulting in cell detachment and collapse.
4. **Rac1 inhibition:** PLXNC1 also recruits the GTPase-activating protein for Rac1, leading to Rac1 inactivation and subsequent actin depolymerization.
5. **FARP2 recruitment:** PLXNC1 binds FARP2 (FERM, ARH/RhoGEF, and Pleckstrin domain protein 2), which activates RhoA, promoting actomyosin contraction.

The net effect of PLXNC1 signaling is typically repulsive or inhibitory—reducing cell adhesion, inhibiting migration, and promoting growth cone collapse in neurons. However, in specific cellular contexts, PLXNC1 signaling can also promote cell survival and proliferation through the activation of the PI3K/AKT pathway.

#### 3.1.2 Integrin-Mediated Signaling

SEMA7A also functions as a ligand for several integrins, including αvβ1, α5β1, and α9β1. The integrin-binding site on SEMA7A has been mapped to a conserved RGD (Arg-Gly-Asp) motif within the SEMA domain, although the exact residues involved differ from the canonical RGD sequence found in fibronectin. Integrin binding to SEMA7A activates the canonical integrin signaling cascade:

1. **FAK activation:** Integrin engagement leads to autophosphorylation of Focal Adhesion Kinase (FAK) at Tyr397.
2. **Src recruitment:** Phosphorylated FAK recruits Src family kinases, which phosphorylate additional tyrosine residues on FAK, creating docking sites for adaptor proteins.
3. **PI3K/AKT pathway:** The FAK/Src complex activates PI3K, leading to AKT phosphorylation and activation of downstream survival and proliferation pathways.
4. **MAPK/ERK pathway:** Integrin signaling also activates the Ras/Raf/MEK/ERK cascade, promoting cell proliferation and differentiation.
5. **Rho family GTPases:** Integrin engagement activates Rac1 and Cdc42, promoting lamellipodia and filopodia formation, respectively, and driving cell migration.

The integrin-mediated signaling of SEMA7A is generally pro-adhesive and pro-migratory, contrasting with the anti-adhesive effects of PLXNC1 signaling. The balance between these two receptor systems determines the net cellular response to SEMA7A.

### 3.2 SEMA7A in Immune Regulation

SEMA7A is expressed on multiple immune cell types, including activated T cells, macrophages, dendritic cells, and natural killer cells. Its expression is markedly upregulated upon immune activation, and it plays critical roles in both innate and adaptive immunity.

#### 3.2.1 Macrophage Function

SEMA7A is a key regulator of macrophage polarization and function. During monocyte-to-macrophage differentiation, SEMA7A expression is dramatically upregulated through both transcriptional and post-transcriptional mechanisms. The RNA-binding protein QKI stabilizes SEMA7A mRNA, allowing sustained protein expression in differentiated macrophages.

SEMA7A promotes the M1 (pro-inflammatory) macrophage phenotype while suppressing the M2 (anti-inflammatory) phenotype. This polarization effect is mediated through integrin signaling that activates NF-κB and AP-1 transcription factors, leading to the expression of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. In the context of atherosclerosis, macrophage-derived SEMA7A drives disease progression through the integrin β1/JNK/MSR1 axis, promoting foam cell formation and plaque instability.

SEMA7A also regulates macrophage-mediated lymphatic remodeling during postpartum mammary gland involution. The GPI-anchored SEMA7A on macrophages interacts with integrins on lymphatic endothelial cells, promoting lymphangiogenesis and facilitating tissue remodeling.

#### 3.2.2 T Cell Regulation

SEMA7A is expressed on activated T cells and functions as a costimulatory molecule. It promotes T cell proliferation and cytokine production through integrin-mediated signaling. In T cell anergy, the transcription factor EGR2 directly regulates SEMA7A expression, and this pathway is critical for maintaining the anergic state.

In atopic dermatitis, SEMA7A regulates the expression of IL-4 and IL-33, key cytokines in the type 2 immune response. SEMA7A expression correlates with disease severity, suggesting that it may serve as a biomarker and therapeutic target for this condition.

#### 3.2.3 Dendritic Cells

SEMA7A on dendritic cells modulates their ability to stimulate T cells. It also affects dendritic cell migration and phagocytosis, although the precise mechanisms remain under investigation.

### 3.3 SEMA7A in Neural Development and Function

SEMA7A was originally identified as an axon guidance molecule that promotes axonal outgrowth in the olfactory bulb. It is expressed in the olfactory epithelium and guides olfactory sensory neuron axons to their targets in the olfactory bulb. The GPI anchor allows SEMA7A to be released from the cell surface and function as a diffusible chemoattractant.

In the developing neocortex, SEMA7A forms heterodimers with SEMA4D that are essential for proper neuronal migration and axonal pathfinding. The heterodimerization is required for the correct membrane targeting of both proteins, and disruption of this interaction leads to severe cortical wiring defects.

SEMA7A also regulates axon outgrowth in subcutaneous white adipose tissue. This function is critical for adipose tissue innervation, which in turn regulates lipolysis, adipogenesis, and thermogenesis. Mice lacking Sema7a in adipose tissue show reduced sympathetic innervation and impaired metabolic function.

### 3.4 SEMA7A in Angiogenesis and Vascular Biology

SEMA7A has pro-angiogenic properties, promoting endothelial cell proliferation, migration, and tube formation. In macrophages of mammary tumor-bearing mice, SEMA7A exerts a pro-angiogenic effect that supports tumor growth. The pro-angiogenic activity is mediated through integrin signaling that activates the PI3K/AKT and MAPK/ERK pathways in endothelial cells.

SEMA7A also promotes endothelial-to-mesenchymal transition (EndMT) through the ATF3-mediated TGF-β2/Smad signaling pathway. EndMT is a process by which endothelial cells acquire mesenchymal characteristics, and it contributes to cardiac fibrosis, pulmonary hypertension, and other vascular pathologies.

In atherosclerosis, SEMA7A expression is upregulated by disturbed blood flow. The mechanosensitive upregulation of SEMA7A in endothelial cells promotes the development of atherosclerotic lesions through multiple mechanisms, including increased leukocyte adhesion, endothelial dysfunction, and smooth muscle cell phenotypic switching.

### 3.5 SEMA7A in Bone and Cartilage Homeostasis

SEMA7A plays a critical role in bone formation and remodeling. It is expressed by osteoblasts and promotes osteoblast differentiation and bone formation through integrin-mediated signaling. Polymorphisms in SEMA7A have been associated with bone mineral density and fracture risk in postmenopausal Korean women.

In articular cartilage repair, SEMA7A regulates the balance between cartilaginous and fibrous tissue formation. This balance is critical for the quality of cartilage repair, with excessive fibrous tissue formation leading to poor functional outcomes.

### 3.6 SEMA7A in Metabolic Regulation

SEMA7A protects against high-fat diet-induced obesity and hepatic steatosis by regulating adipo/lipogenesis. The mechanism involves SEMA7A-mediated inhibition of adipocyte differentiation and lipid accumulation. This metabolic function is mediated through integrin signaling that modulates the expression of key adipogenic transcription factors including PPARγ and C/EBPα.

### 3.7 Protein-Protein Interaction Network

The SEMA7A interaction network includes:

| **Interactor** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| PLXNC1 | High-affinity receptor binding | Repulsive signaling, cytoskeletal collapse |
| ITGAV/ITGB1 (αvβ1) | Integrin receptor binding | Adhesion, migration, proliferation |
| ITGA5/ITGB1 (α5β1) | Integrin receptor binding | Adhesion, migration |
| ITGA9/ITGB1 (α9β1) | Integrin receptor binding | Adhesion, migration |
| SEMA4D | Heterodimerization (cis) | Membrane targeting, neocortical wiring |
| IGFBP-3 | Juxtacrine stimulation | IL-17RB upregulation in pancreatic cancer |
| QKI | mRNA stabilization | Post-transcriptional regulation |
| KDM4A | Downstream effector | DNA replication regulation in breast cancer |
| PDK1/SGK3/YTHDC1 | Signaling axis | VSMC phenotypic switching in AAA |

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Kallmann Syndrome and Congenital Hypogonadotropic Hypogonadism

Kallmann syndrome (KS) is a rare genetic disorder characterized by the combination of hypogonadotropic hypogonadism (HH) and anosmia (absence of sense of smell). SEMA7A mutations have been identified in patients with KS and congenital hypogonadotropic hypogonadism (CHH).

A novel heterozygous intron mutation in SEMA7A causing Kallmann syndrome in a female patient was reported by Zhao et al.. The mutation, located in an intronic region, affects mRNA splicing and leads to reduced SEMA7A protein expression. This finding established SEMA7A as a causative gene for KS, expanding the genetic heterogeneity of this condition.

Mutation screening of SEMA7A in patients with CHH identified additional variants, including missense mutations in the SEMA domain that affect protein folding or receptor binding. The oligogenic inheritance pattern of CHH suggests that SEMA7A mutations may act in concert with mutations in other genes, including FGFR1, KAL1, and PROKR2. This oligogenic model explains the variable penetrance and expressivity observed in CHH families.

The mechanism by which SEMA7A mutations cause KS involves disrupted axon guidance of gonadotropin-releasing hormone (GnRH) neurons. During development, GnRH neurons migrate from the olfactory placode to the hypothalamus, and this migration is guided by SEMA7A-mediated axon guidance signals. Mutations that impair SEMA7A function disrupt this migratory process, leading to failed GnRH neuron migration and consequent hypogonadotropic hypogonadism.

### 4.2 JMH Blood Group Antigens

The JMH (John Milton Hagen) blood group system consists of six high-prevalence antigens located on the SEMA7A protein. These antigens are:

| **Antigen** | **Molecular Basis** |
|---|---|
| JMH1 | Unknown; associated with the JMH-negative phenotype |
| JMH2 | Single nucleotide change in SEMA7A |
| JMH3 | Single nucleotide change in SEMA7A |
| JMH4 | Single nucleotide change in SEMA7A |
| JMH5 | Single nucleotide change in SEMA7A |
| JMH6 | Single nucleotide change in SEMA7A |

The JMH-negative phenotype can be inherited (rare) or acquired. Inherited JMH-negative individuals lack SEMA7A expression on their red blood cells due to homozygous or compound heterozygous mutations in SEMA7A. These individuals can develop anti-JMH alloantibodies upon exposure to JMH-positive red blood cells through transfusion or pregnancy. The anti-JMH alloantibodies can cause hemolytic transfusion reactions, although the clinical significance varies depending on the antibody titer and thermal amplitude.

Acquired JMH-negative phenotypes are more common and result from the loss of SEMA7A from the red blood cell surface due to proteolytic cleavage or GPI anchor loss. This acquired form is often associated with hematological malignancies or autoimmune disorders.

### 4.3 Cancer-Associated Mutations and Expression Alterations

SEMA7A is overexpressed in multiple cancer types, and its expression level correlates with poor prognosis. Pan-cancer analyses have identified SEMA7A as a prognostic biomarker in kidney renal clear cell carcinoma, lung adenocarcinoma, colorectal cancer, pancreatic cancer, breast cancer, and adrenocortical carcinoma.

The molecular mechanisms of SEMA7A overexpression in cancer include:

1. **Gene amplification:** Focal amplification of the 15q22-q23 region containing SEMA7A has been observed in some tumors.
2. **Epigenetic dysregulation:** Hypomethylation of the SEMA7A promoter leads to transcriptional activation in cancer cells.
3. **Transcriptional activation:** Oncogenic transcription factors, including SOX9 and MYC, directly activate SEMA7A transcription.
4. **Post-transcriptional deregulation:** Loss of tumor-suppressive miRNAs (e.g., miR-28-5p) or overexpression of ceRNAs (e.g., LOXL1-AS1) leads to increased SEMA7A mRNA stability and translation.
5. **Post-translational stabilization:** CHST11-mediated chondroitin sulfate modification promotes SEMA7A expression and contributes to TKI resistance in lung cancer.

### 4.4 Specific Pathogenic Variants

| **Variant** | **Type** | **Disease Association** | **Mechanism** |
|---|---|---|---|
| c.IVS+1G>A (intron mutation) | Splicing | Kallmann syndrome | Aberrant splicing, reduced protein expression |
| p.Arg153Cys | Missense | CHH | Disrupted PLXNC1 binding |
| p.Asp155Asn | Missense | CHH | Disrupted PLXNC1 binding |
| p.Gly346Arg | Missense | CHH | Protein misfolding |
| Multiple SNPs | Polymorphism | Bone mineral density | Altered expression or function |
| Multiple SNPs | Polymorphism | SLE susceptibility | Altered immune regulation |

### 4.5 Clinical Differential Diagnosis

The clinical presentation of SEMA7A-related disorders is highly variable, reflecting the pleiotropic functions of the protein. The differential diagnosis for SEMA7A-related Kallmann syndrome includes:

- **Other genetic causes of CHH:** Mutations in KAL1, FGFR1, PROKR2, PROK2, CHD7, and FGF8.
- **Acquired hypogonadotropic hypogonadism:** Due to pituitary tumors, infiltrative diseases, or medications.
- **Constitutional delay of growth and puberty:** A benign variant of normal development.

For JMH-negative blood phenotypes, the differential diagnosis includes:

- **Inherited JMH-negative:** Due to SEMA7A mutations.
- **Acquired JMH-negative:** Due to proteolytic cleavage or GPI anchor loss in hematological disorders.
- **Other blood group system null phenotypes:** e.g., Rh-null, K0, or Co(a-b-).

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Semaphorin Mimicry

Several viruses encode semaphorin homologs that mimic host semaphorins to subvert immune responses. The vaccinia virus (VACV) encodes A39R, a secreted semaphorin that shares structural homology with SEMA7A. A39R binds to PLXNC1 with high affinity and inhibits dendritic cell phagocytosis and migration. This viral semaphorin mimicry represents an immune evasion strategy that dampens antiviral immune responses.

The A39R protein is a 50–55 kDa secreted glycoprotein that is expressed during the early phase of VACV infection. It is not essential for viral replication in vitro but affects the outcome of infection in a murine intradermal model, suggesting that it modulates the host immune response in vivo.

### 5.2 Bacterial Interactions

The gut commensal Bacteroides fragilis produces extracellular vesicles that regulate macrophage polarization through the promotion of Sema7a expression. This interaction has implications for type 2 diabetes (T2D) and its vascular complications. The B. fragilis extracellular vesicles induce Sema7a expression in macrophages, promoting an M2-like anti-inflammatory phenotype that may protect against T2D-associated inflammation.

Porphyromonas gingivalis, a major periodontal pathogen, modulates gene expression in head and neck cancer cells, and SEMA7A is among the genes affected. This interaction may contribute to the increased cancer risk associated with periodontal disease.

### 5.3 Parasitic Infections

In Schistosoma japonicum infection, SEMA7A expression is altered in the liver during the chronic pathogenic stage. The functional significance of this alteration remains to be fully characterized, but it may contribute to the hepatic fibrosis and immune dysregulation associated with chronic schistosomiasis.

### 5.4 Endogenous Retroviruses

Human endogenous retrovirus (HERV)-K119 env has been shown to affect THP-1 monocytic cell differentiation, and this process involves changes in SEMA7A expression. The interaction between HERV elements and SEMA7A suggests a complex regulatory network that links retroelement activity to immune cell function.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Targeting Strategies

The pleiotropic functions of SEMA7A in cancer, cardiovascular disease, and immune disorders make it an attractive therapeutic target. Several strategies are being explored:

#### 6.1.1 Monoclonal Antibodies

Anti-SEMA7A monoclonal antibodies have been developed and tested in preclinical models. In a murine model of advanced breast carcinoma, suppression of tumor-derived SEMA7A with neutralizing antibodies impaired tumor progression and metastasis. The antibodies block SEMA7A binding to both PLXNC1 and integrin receptors, thereby inhibiting downstream signaling.

The development of humanized anti-SEMA7A antibodies for clinical use is ongoing. These antibodies would be used for the treatment of SEMA7A-overexpressing tumors, including breast, lung, and pancreatic cancers.

#### 6.1.2 Small-Molecule Inhibitors

Small-molecule inhibitors targeting the SEMA7A-PLXNC1 interaction are being developed. These compounds bind to the SEMA domain of SEMA7A or the SEMA domain of PLXNC1, blocking the protein-protein interaction. Structure-based drug design using the co-crystal structure of the SEMA7A-PLXNC1 complex (PDB: 4UX8) has identified several lead compounds with micromolar affinity.

Inhibitors of the SEMA7A-integrin interaction are also being explored. Peptide mimetics of the integrin-binding site on SEMA7A have been shown to competitively inhibit SEMA7A-integrin binding and block SEMA7A-mediated cell migration.

#### 6.1.3 Gene Therapy and RNA-Based Approaches

RNA interference (RNAi) approaches using short hairpin RNA (shRNA) or small interfering RNA (siRNA) targeting SEMA7A have been validated in preclinical models. Silencing of SEMA7A in breast cancer cells attenuates tumor progression and metastasis. Lipid nanoparticle (LNP)-formulated siRNA targeting SEMA7A is being evaluated for clinical development.

Antisense oligonucleotides (ASOs) targeting SEMA7A mRNA are also being developed. These ASOs can be designed to specifically target the SEMA7A transcript while sparing other semaphorin family members.

#### 6.1.4 Natural Compounds

Several natural compounds have been shown to modulate SEMA7A expression:

- **Glycitein**, a component of Zhi-Zi-Chi decoction, alleviates anxiety via inosine enrichment mediated by Akkermansia muciniphila to regulate MT3-Sema7a interaction.
- **β-Caryophyllene** modulates SEMA7A expression in a DSS-induced colitis model.
- **Tanreqing injection** regulates Sema7a/Plxnc1 signaling to alleviate LPS-induced acute lung injury.
- **Luteolin** affects SEMA7A expression in the context of late-onset depression.

### 6.2 Pharmacogenomic Considerations

SEMA7A polymorphisms may influence drug response and toxicity. The association of SEMA7A SNPs with bone mineral density suggests that these variants may affect the response to osteoporosis therapies. Similarly, SEMA7A expression levels may predict response to immunotherapy in cancer patients, with high SEMA7A expression associated with an immunosuppressive tumor microenvironment and poor immunotherapy response.

### 6.3 Drug Resistance Mechanisms

SEMA7A contributes to therapeutic resistance in multiple cancer types:

- **ER+ breast cancer:** SEMA7A is hormonally regulated and drives therapeutic resistance to endocrine therapies. The SIM2s/SEMA7A switch drives therapeutic resistance in ER+ breast cancer.
- **Lung cancer:** CHST11-mediated SEMA7A expression contributes to TKI resistance.
- **Triple-negative breast cancer:** SEMA7A promotes chemoresistance and metastasis in young women.
- **Pancreatic cancer:** The LOXL1-AS1/miR-28-5p/SEMA7A axis facilitates pancreatic cancer progression and may contribute to chemoresistance.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 8484 | https://www.ncbi.nlm.nih.gov/gene/8484 |
| Ensembl | ENSG00000138623 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000138623 |
| UniProt | O75326 | https://www.uniprot.org/uniprotkb/O75326 |
| RCSB PDB | 3NVQ, 4UX8 | https://www.rcsb.org/structure/3NVQ |
| OMIM | 607961 | https://www.omim.org/entry/607961 |
| HGNC | 10722 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:10722 |
| ClinVar |

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)